Evidence mapPaperPMID 33150478Full record

SynthesisEuropean journal of clinical pharmacology2021

Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis.

Qian Xiang, Xiao-Dan Zhang, Guang-Yan Mu, Zhe Wang, Zhi-Yan Liu, Qiu-Fen Xie, Kun Hu, Zhuo Zhang, Ling-Yue Ma, Jie Jiang and 1 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Qian XiangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Xiao-Dan ZhangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Guang-Yan MuDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Zhe WangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Zhi-Yan LiuDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Qiu-Fen XieDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Kun HuDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Zhuo ZhangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Ling-Yue MaDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Jie JiangDepartment of Cardiology, Peking University First Hospital, Beijing, 100034, China.
Yi-Min CuiDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China. cui.pharm@pkufh.com.ORCID http://orcid.org/0000-0002-4186-1005
Peking University · CN

Funding

National Key R&D Program of China 2016YFC0904900National Natural Science Foundation 81872940, 81973395National Science and Technology Major Projects for Major New Drugs Innovation and Development of China 2017ZX09304028, 2017ZX09101001Natural Science Foundation of Beijing Municipality 7171012
6 · The paper itself

Abstract

purposeA meta-analysis was performed to evaluate the correlation between single-nucleotide polymorphisms (SNPs) and risk of statin-induced myopathy (SIM).

methodsWe retrieved the studies published on SIM until April 2019 from the PubMed, Embase, and Cochrane Library databases. We collected data from 32 studies that analyzed 10 SNPs in five genes and included 21,692 individuals and nine statins.

resultsThe analysis of the heterozygous (p = 0.017), homozygous (p = 0.002), dominant (p = 0.005), and recessive models (p = 0.009) of SLCO1B1 rs4149056 showed that this SNP increases the risk of SIM. Conversely, heterozygous (p = 0.048) and dominant models (p = 0.030) of SLCO1B1 rs4363657 demonstrated that this SNP is associated with a reduced risk of SIM. Moreover, an increased risk of SIM was predicted for carriers of the rs4149056 C allele among simvastatin-treated patients, whereas carriers of the GATM rs9806699 A allele among rosuvastatin-treated patients had a lower risk of SIM.

conclusionThe meta-analysis revealed that the rs4149056 and rs4363657 SNPs in SLCO1B1 and the rs9806699 SNP in GATM are correlated with the risk of SIM.

Indexed as

AmidinotransferasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1Muscular DiseasesPolymorphism, Single NucleotideRiskAmidinotransferasesglycine amidinotransferaseHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanHydroxymethylglutaryl-CoA reductase inhibitorMeta-analysisMitochondrial myopathySingle-nucleotide polymorphism

Identifiers

PMID33150478
OpenAlexW3095237429

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.